The Seeking Alpha analysts who have covered Boston Scientific Corporation (NYSE: BSX ) since the beginning of this year have concerns about the company. The last nine ratings, since January 10, 2024 have all been Holds. To find a BuyRobert F. Abbott has been investing his family’s accounts since 1995, and in 2010 added options, mainly covered calls and collars with long stocks. He is a freelance writer, and his projects include a website that provides information for new and intermediate-level mutual fund i ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Growth S ...

U.S. stock markets have been witnessing an impressive rally since the beginning of 2023, barring some minor hurdles. Wall Street’s bull run has got an added boost this year, to the surprise of a large section of financial pandits, who indiscriminately warned of overvaluation. Year to date, the three major stock indexes — the Dow, the S&P 500 and the Nasdaq Composite — have advanced 11.7%, 22.6%, and 26%, respectively. Consequently, various S&P 500 stocks have climbed this year. Here we have selected five S& ...

On Wednesday, Boston Scientific Corporation BSX released the results of the primary endpoint of the ACURATE IDE trial of ACURATE neo2 Aortic Valve System for patients with severe, symptomatic aortic stenosis at risk of open-heart surgery.The data were presented at Transcatheter Cardiovascular Therapeutics 2024, the annual scientific symposium of the Cardiovascular Research Foundation.This randomized trial evaluated the ACURATE neo2 valve, the company’s second-generation transcatheter aortic valve replacemen ...

MARLBOROUGH, Mass. and WASHINGTON, Oct. 30, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the results of the primary endpoint of the ACURATE IDE clinical trial, which evaluated the ACURATE neo2™ Aortic Valve System in the treatment of patients with severe, symptomatic aortic stenosis at low, intermediate, high and extreme risk of open-heart surgery. The data were presented as a late-breaking clinical trial at Transcatheter Cardiovascular Therapeutics® (TCT®) 2024, the annual ...

Key TakeawaysBoston Scientific shares fell Wednesday as its third-quarter profit missed estimates.The medical device maker's adjusted earnings per share and revenue were more than expected, as sales of its cardiovascular products surged.Boston Scientific gave a mixed updated full-year forecast. Boston Scientific (BSX) shares fell Wednesday when the medical equipment manufacturer's third-quarter profit fell and its GAAP earnings per share (EPS) came in short of its guidance. The company reported net income d ...

Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 63 cents for the third quarter of 2024, up 26% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 8.6% and also exceeded the company’s adjusted earnings per share guidance range of 57-59 cents per share.The quarter’s adjustments included certain amortization expenses, acquisition/divestitures-related net charges, and restructuring and restructuring-related charges, among others.Reported EPS for the third q ...

Financial Data and Key Metrics Changes - In Q3 2024, total company operational sales grew 19% and organic sales grew 18%, exceeding the guidance range of 13% to 15% [5][17] - Adjusted EPS for Q3 was $0.63, a 27% increase, surpassing the guidance range of $0.57 to $0.59 [5][17] - Adjusted operating margin for Q3 was 27.2%, expanding 110 basis points year-over-year [18] Business Line Data and Key Metrics Changes - Cardiology sales grew 29%, with Interventional Cardiology Therapies growing 14% [10] - Electrophysiology sales surged 177%, driven by commercial execution and increased procedure volumes [13] - Urology sales increased by 10%, with double-digit growth in Stone Management and Prostate Health [7][8] - Endoscopy sales grew 7% organically, with strong growth in the US [8] Market Data and Key Metrics Changes - US operational sales grew 24%, with double-digit growth in six of eight business units [6] - Europe, Middle East, and Africa (EMEA) grew 14% operationally, driven by above-market performance in Electrophysiology [6] - Asia Pacific sales grew 12% operationally, with strong performance in China and Australia [7] Company Strategy and Development Direction - The company continues to focus on category leadership through innovation and clinical evidence generation [5] - Plans to close the acquisition of Axonics in Q4 2024, enhancing the Urology business [8] - The company aims to outperform markets and achieve double-digit growth in adjusted earnings per share in 2025 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining top-tier financial performance and highlighted strong momentum across the portfolio, particularly in AF solutions [5][6] - The company anticipates continued growth driven by new product launches and expanding market share in existing accounts [46][47] Other Important Information - The company expects full-year 2024 adjusted EPS to be in the range of $2.45 to $2.47, representing growth of 20% to 21% [21] - The operational tax rate for Q4 is expected to be approximately 13.5% [21] Q&A Session All Questions and Answers Question: Upcoming OPTION trial and its impact - Management highlighted the positive implications of the concomitant reimbursement for WATCHMAN and FARAPULSE, emphasizing the safety and efficiency of both procedures [26][27] Question: FARAPULSE results and market share expectations - Management expressed confidence in FARAPULSE exceeding the previously communicated range of 40% to 60% of global AF ablations by 2026 due to rapid adoption by physicians [29] Question: AVANT GUARD trial observations - Management reassured that the observations from the AVANT GUARD trial were not life-threatening and emphasized confidence in the overall safety and efficacy of the FARAPULSE system [43][71] Question: Capacity and supply chain concerns - Management confirmed there are no anticipated supply shortages for FARAPULSE, despite high demand [63] Question: 2025 market growth drivers - Management identified several tailwinds for growth in 2025, including new product launches and expanding market share in existing accounts [46][47]

For the quarter ended September 2024, Boston Scientific (BSX) reported revenue of $4.21 billion, up 19.3% over the same period last year. EPS came in at $0.63, compared to $0.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $4.03 billion, representing a surprise of +4.35%. The company delivered an EPS surprise of +8.62%, with the consensus EPS estimate being $0.58.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

Boston Scientific (BSX) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.58 per share. This compares to earnings of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.62%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $0.58 per share when it actually produced earnings of $0.62, delivering a surprise of 6.90%.Over the last four qua ...